ClearPoint Neuro 将来の成長

Future 基準チェック /26

ClearPoint Neuroは、9.8%と29.8%でそれぞれ年率9.8%で利益と収益が成長すると予測される一方、EPSはgrowで12.3%年率。

主要情報

9.8%

収益成長率

12.3%

EPS成長率

Medical Equipment 収益成長	17.0%
収益成長率	29.8%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	11 Dec 2024

今後の成長に関する最新情報

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 09

Recent updates

After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar

Dec 10

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Sep 14

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Aug 16

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

Jul 11

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 09

ClearPoint Neuro: Macro-Induced Multiple Compression

Apr 25

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Apr 19

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Mar 15

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Jan 04

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Dec 06

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Nov 06

業績と収益の成長予測

NasdaqCM:CLPT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	65	N/A	N/A	N/A	1
12/31/2025	39	-16	N/A	N/A	3
12/31/2024	32	-18	N/A	N/A	3
9/30/2024	30	-18	-9	-9	N/A
6/30/2024	28	-18	-10	-9	N/A
3/31/2024	26	-21	-13	-12	N/A
12/31/2023	24	-22	-15	-14	N/A
9/30/2023	22	-22	-17	-16	N/A
6/30/2023	22	-21	-19	-18	N/A
3/31/2023	21	-18	-19	-18	N/A
12/31/2022	21	-16	-17	-16	N/A
9/30/2022	20	-16	-18	-17	N/A
6/30/2022	19	-16	-17	-16	N/A
3/31/2022	17	-16	-15	-15	N/A
12/31/2021	16	-14	-13	-13	N/A
9/30/2021	16	-12	-12	-12	N/A
6/30/2021	15	-9	-10	-10	N/A
3/31/2021	14	-7	-8	-8	N/A
12/31/2020	13	-7	-8	-8	N/A
9/30/2020	12	-7	-6	-6	N/A
6/30/2020	12	-6	-6	-5	N/A
3/31/2020	12	-6	-5	-5	N/A
12/31/2019	11	-6	-3	-3	N/A
9/30/2019	10	-5	-3	-3	N/A
6/30/2019	9	-5	-3	-3	N/A
3/31/2019	8	-6	-3	-3	N/A
12/31/2018	7	-6	-5	-5	N/A
9/30/2018	7	-7	-6	-6	N/A
6/30/2018	7	-7	N/A	-6	N/A
3/31/2018	7	-7	N/A	-7	N/A
12/31/2017	7	-7	N/A	-6	N/A
9/30/2017	7	-7	N/A	-5	N/A
6/30/2017	7	-8	N/A	-5	N/A
3/31/2017	6	-8	N/A	-6	N/A
12/31/2016	6	-8	N/A	-6	N/A
9/30/2016	6	-8	N/A	-6	N/A
6/30/2016	5	-5	N/A	-6	N/A
3/31/2016	5	-7	N/A	-7	N/A
12/31/2015	5	-8	N/A	-9	N/A
9/30/2015	4	-9	N/A	-9	N/A
6/30/2015	3	-13	N/A	-10	N/A
3/31/2015	4	-11	N/A	-9	N/A
12/31/2014	4	-5	N/A	-7	N/A
9/30/2014	4	-4	N/A	-7	N/A
6/30/2014	4	-4	N/A	-6	N/A
3/31/2014	3	-4	N/A	-7	N/A
12/31/2013	4	-7	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CLPT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CLPT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CLPT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CLPTの収益 ( 29.8% ) US市場 ( 9.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: CLPTの収益 ( 29.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CLPTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/23 11:13
終値	2024/12/20 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

ClearPoint Neuro, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。6

アナリスト	機関
Andrew D'Silva	B. Riley Securities, Inc.
Kyle Bauser	B. Riley Securities, Inc.
Sally Yanchus	Brookline Capital Markets

ClearPoint Neuro 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 21% to US$15.67

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Full Year of 2024

Price target increased by 18% to US$11.83

ClearPoint Neuro, Inc. Raises Revenue Guidance for the Year 2024

Consensus EPS estimates upgraded to US$0.66 loss

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar

ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

Price target increased by 21% to US$15.67

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Full Year of 2024

ClearPoint Neuro, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%

Price target increased by 18% to US$11.83

Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

ClearPoint Neuro, Inc. Raises Revenue Guidance for the Year 2024

Insufficient new directors

ClearPoint Neuro, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%

ClearPoint Neuro, Inc.(NasdaqCM:CLPT) dropped from Russell Small Cap Completeness Index

ClearPoint Neuro, Inc. Initiates Its Full Market Release of the Smartframe

Consensus EPS estimates upgraded to US$0.66 loss

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ClearPoint Neuro, Inc. Announces FDA Clearance of Prism Bone Anchor Accessory

ClearPoint Neuro, Inc. Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System

ClearPoint Neuro: Macro-Induced Multiple Compression

ClearPoint Neuro, Inc. to Report Q1, 2024 Results on May 07, 2024

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

ClearPoint Neuro, Inc., Annual General Meeting, May 15, 2024

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2024

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Full year 2023 earnings: EPS and revenues exceed analyst expectations

ClearPoint Neuro, Inc. Announces Preclinical Results of an in Vivo Validation Study Have Been Published in the Journal of Neurosurgery

President exercised options and sold US$69k worth of stock

New minor risk - Shareholder dilution

ClearPoint Neuro, Inc. to Report Q4, 2023 Results on Mar 12, 2024

ClearPoint Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $15.000011 million.

ClearPoint Neuro, Inc. has filed a Follow-on Equity Offering.

ClearPoint Neuro, Inc. Announces FDA Clearance and First-In-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

Now 21% undervalued

Clearpoint Neuro Receives 510(K) Clearance for Smartframe or Stereotactic System

ClearPoint Neuro, Inc. Provides Revenue Guidance for the Full Year 2024

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

ClearPoint Neuro, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Consensus EPS estimates fall by 36%

ClearPoint Neuro, Inc. Reaffirms Its Revenue Guidance for Full Year 2023

Second quarter 2023 earnings: EPS misses analyst expectations

ClearPoint Neuro, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Consensus EPS estimates fall by 13%

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2023

Price target increased by 19% to US$22.00

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Full year 2022 earnings: EPS exceeds analyst expectations

ClearPoint Neuro, Inc. to Report Q4, 2022 Results on Mar 01, 2023

ClearPoint Neuro, Inc. Provides Revenue Guidance for the Year 2023

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro, Inc. Announces First Patient Enrolled in Glioblastoma Trial Using Clearpoint Prism Neuro Laser Therapy System At Skåne University Hospital in Sweden

Price target increased to US$20.25

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2022

ClearPoint Neuro, Inc. to Report Q3, 2022 Results on Nov 08, 2022

ClearPoint Neuro, Inc. Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System

ClearPoint Neuro, Inc. Announces Appointment of Mazin Sabra as Chief Operating Officer

ClearPoint Neuro, Inc. Announces FDA Clearance for Software Version 2.1

ClearPoint Neuro: Continuous Great Execution

President notifies of intention to sell stock

ClearPoint Neuro: Picks & Shovels Galore